Although the revenue and EPS for Revance Therapeutics, Inc. (RVNC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%.– Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million.– Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%.– In August, DAXXIFY was approved by the FDA for the treatment of cervical dy.
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Revance Therapeutics (RVNC) to Release Quarterly Earnings on Wednesday kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price […]